Monday, 26 Aug 2019

You are here

Depression Increases Risk of Systemic Lupus Erythematosus

Twenty-year data from the Nurses’ Health Study (NHS) suggests that depression is associated with a 2-fold increased frequency of systemic lupus erythematosus (SLE) - the question is why?

An analysis of 194,483 women in the NHS sought to identify incident SLE cases meeting ACR criteria (with 4 or more criteria) bases on self-report and confirmed by medical record review. Depression was based on a clinician’s diagnosis of depression, antidepressant use, or a score of less than 60 on the 5-item Mental Health Inventory (MHI-5).

Among from 194 483 women (28-93 years of age) in the NHS, there were 145 incident cases of SLE.

Women with depression had over a 2 fold increased risk of SLE (HR, 2.67; 95% CI, 1.91-3.75; P < .001) compared to those with no depression.  This risk was largely unchanged after adjustment for body mass index, cigarette smoking, and oral contraception and postmenopausal hormone use.

The Lupus risk was evident regardless of the measure used to establish depression - clinician’s diagnosis, antidepressant use or MHI-5 scores.

Why would depression may be associated with increased risk of SLE remains unclear. Depression may occur as part of a neuropsychiatric manifestation of lupus.  Some research indicates immunologic abnormalities in those with depression and patients with depression have a slightly higher rate of autoantibodies. 

Limitations of the NHS and this kind of research are several. First, nurses who are enrolled may not be truly representative of the population, as nurses tend to be more more homogeneous as a group and tend to be generally white, thinner, more health-conscious, highly educated.  Moreover this comes with the limitations of an observational study. Hence these findings are best at generating hypotheses that can be further studied with intervention and other forms of randomized trials.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

With Autoimmunity, Checkpoint Inhibitors Can Be Used

Among patients with pre-existing autoimmune diseases who developed cancer and were treated with immune checkpoint inhibitors (ICI), flares of the underlying disease and other immune-related adverse events were common, a retrospective study conducted in France showed.

New EULAR/ACR Classification Criteria for SLE

The European League Against Rheumatism (EULAR) and the American College of Rheumatology (ACR) have jointly developed new classification criteria for systemic lupus erythematosus (SLE); prompted by the need for criteria that were both highly sensitive and specific. The net result is improved sensitivity and specificity, but the use of positive ANA requirement along with a longer list of weighted criteria ensures its utility in SLE research (including early or latent SLE), but not clinical practice.

Sjogren's Syndrome at Risk for Psychiatric Disorders

A population-based claims study from Taiwan shows significantly increased incidences of depressive disorder, anxiety disorder, and sleep disorder in patients with primary Sjögren’s syndrome (pSS). 

Abatacept Disappoints in Systemic Sclerosis

A 12‐month, Phase 2 trial has shown that subcutaneous abatacept was well tolerated in patients with diffuse cutaneous systemic sclerosis (dcSSc), but failed to significantly change the skin outcomes as measured by the change in modified Rodnan skin score (mRSS)

FDA AAC Splits Vote in Favor of Nintedanib for Scleroderma Interstitial Lung Disease

The FDA convened Arthritis Advisory Committee to consider nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease (SSc-ILD) and voted 10-7 in favor of approving the drug for this new indication.